Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Serina Therapeutics (SER) Shares Outstanding (Weighted Average) (2017 - 2025)

Serina Therapeutics (SER) has disclosed Shares Outstanding (Weighted Average) for 9 consecutive years, with $10.2 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 38.47% to $10.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.2 million through Dec 2025, up 38.47% year-over-year, with the annual reading at $10.2 million for FY2025, 38.47% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $10.2 million in Q4 2025 for Serina Therapeutics, up from $10.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $37.9 million in Q4 2021 to a low of $37833.0 in Q2 2021.
  • Historically, Shares Outstanding (Weighted Average) has averaged $9.7 million across 5 years, with a median of $5.1 million in 2024.
  • Biggest YoY gain for Shares Outstanding (Weighted Average) was 6507.99% in 2022; the steepest drop was 99.9% in 2022.
  • Year by year, Shares Outstanding (Weighted Average) stood at $37.9 million in 2021, then plummeted by 99.05% to $358511.0 in 2022, then surged by 523.41% to $2.2 million in 2023, then surged by 229.26% to $7.4 million in 2024, then skyrocketed by 38.47% to $10.2 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for SER at $10.2 million in Q4 2025, $10.0 million in Q3 2025, and $10.0 million in Q2 2025.